MX2018010781A - Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias. - Google Patents

Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias.

Info

Publication number
MX2018010781A
MX2018010781A MX2018010781A MX2018010781A MX2018010781A MX 2018010781 A MX2018010781 A MX 2018010781A MX 2018010781 A MX2018010781 A MX 2018010781A MX 2018010781 A MX2018010781 A MX 2018010781A MX 2018010781 A MX2018010781 A MX 2018010781A
Authority
MX
Mexico
Prior art keywords
treatment
dosage regimen
inflammatory conditions
acute exacerbations
exacerbations
Prior art date
Application number
MX2018010781A
Other languages
English (en)
Inventor
De Buck Stefan
Orford Colin
Clarke Cyril
Farrell Colm
Parkin Jacqueline
Original Assignee
Mereo Biopharma 1 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 1 Ltd filed Critical Mereo Biopharma 1 Ltd
Publication of MX2018010781A publication Critical patent/MX2018010781A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un régimen de dosificación para la administración de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1- il]-N-ciclopropil-4-metilbenzamida o un derivado farmacéuticamente aceptable de la misma, específicamente en el tratamiento de exacerbaciones agudas de condiciones inflamatorias.
MX2018010781A 2016-03-08 2016-03-08 Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias. MX2018010781A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2016/050635 WO2017153701A1 (en) 2016-03-08 2016-03-08 Dosage regimen for the treatment of acute exacerbations of inflammatory conditions

Publications (1)

Publication Number Publication Date
MX2018010781A true MX2018010781A (es) 2018-11-09

Family

ID=55646778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010781A MX2018010781A (es) 2016-03-08 2016-03-08 Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias.

Country Status (9)

Country Link
US (1) US10617674B2 (es)
JP (1) JP6741773B2 (es)
KR (1) KR20180119597A (es)
AU (1) AU2016397046B2 (es)
BR (1) BR112018067784A2 (es)
CA (1) CA3016368A1 (es)
MX (1) MX2018010781A (es)
RU (1) RU2709509C1 (es)
WO (1) WO2017153701A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3016488C (en) * 2016-03-08 2023-04-11 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
GB201612238D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
DK3585382T3 (da) * 2017-12-11 2021-08-09 Mereo Biopharma 1 Ltd Anvendelse af 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamid i behandlingen af akutte forværringer af kronisk obstruktiv lungesygdom

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6598603B1 (en) 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
AU2004259662B2 (en) * 2003-06-26 2008-08-07 Mereo Biopharma 1 Limited 5-membered heterocycle-based p38 kinase inhibitors
RU2381219C2 (ru) * 2003-06-26 2010-02-10 Новартис Аг ПРОИЗВОДНЫЕ 5-ЧЛЕННЫХ ГЕТЕРОЦИКЛОВ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ p38
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
US20050277602A1 (en) * 2004-05-21 2005-12-15 Grunstein Michael M Methods employing agonists of P38 map kinase for the treatment of asthma
EP1987022A1 (en) * 2006-02-10 2008-11-05 Pfizer Products Inc. Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives
GB0603684D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
PL2827860T3 (pl) * 2012-03-20 2017-09-29 Mereo Biopharma 1 Limited Zastosowanie pochodnej pirazolowej w leczeniu nagłych zaostrzeń przewlekłej obturacyjnej choroby płuc

Also Published As

Publication number Publication date
BR112018067784A2 (pt) 2019-01-15
JP2019507785A (ja) 2019-03-22
KR20180119597A (ko) 2018-11-02
AU2016397046B2 (en) 2022-05-12
CA3016368A1 (en) 2017-09-14
AU2016397046A1 (en) 2018-09-06
RU2709509C1 (ru) 2019-12-18
WO2017153701A1 (en) 2017-09-14
US10617674B2 (en) 2020-04-14
US20190091203A1 (en) 2019-03-28
JP6741773B2 (ja) 2020-08-19

Similar Documents

Publication Publication Date Title
IL264210A (en) High-dose cannabinoid dosage forms for oral administration
EP3548005A4 (en) EXOSOMES FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
HK1248570A1 (zh) D2o穩定化的藥物製劑
HK1257182A1 (zh) 用於眼部給藥的半氟化的化合物
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
MX2017006217A (es) Polinucleotidos moduladores.
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
IL275484A (en) W/O/W microemulsions for ophthalmic administration
HK1252771A1 (zh) 用於治療眼部病狀的玻璃體內藥物遞送系統
IL250038A0 (en) 4,5 - dehydroisoxazole derivatives used as nampt inhibitors
EP3344232A4 (en) MICELLES FOR DELIVERY OF MUCOADHESIVE MEDICAMENTS
PH12016501841A1 (en) Immunosuppressant formulation
MX2018010782A (es) Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica.
MX2018010781A (es) Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias.
PL3368015T3 (pl) Dostarczanie niesteroidowego leku przeciwzapalnego o przedłużonym uwalnianiu
ZA202001418B (en) Therapeutic indazoles
EP3375456A4 (en) TOPLY ADMINISTERED DELIVERY AGENT
GB201808507D0 (en) Dosage Regime
GB201808473D0 (en) Dosage regime
GB201808101D0 (en) Dosage regime
GB201803298D0 (en) Dosage regime
GB201802679D0 (en) Dosage regime
GB201720541D0 (en) Dosage regime
GB201720544D0 (en) Dosage regime